GlassScriptPhysician profile
Jay S Lipshitz
NPI 1134363278
$3,788.62
in general payments reported to CMS, 2019-2025
29 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $52.14 · 2021: $309 · 2022: $590 · 2023: $937 · 2024: $1,048 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $643.60 | 2019-2025 | |
| Janssen Biotech, INC. | $447.92 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $363.55 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $276.03 | 2021-2025 | Ninlaro, Vpriv |
| E.R. Squibb & Sons, L.L.C. | $242.03 | 2019-2024 | |
| Celgene Corporation | $219.52 | 2021-2024 | Reblozyl |
| Pfizer INC. | $192.24 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.01 | 2019-2025 | |
| Daiichi Sankyo INC. | $169.93 | 2023-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $146.92 | 2021-2024 | Calquence |
| Lilly USA, LLC | $115.09 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $105.86 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $86.00 | 2020-2023 | Tavalisse, Rezlidhia |
| Eisai INC. | $84.63 | 2023-2024 | |
| Tersera Therapeutics LLC | $69.84 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $68.69 | 2024-2025 | Pyrukynd |
| Genmab U.S., INC. | $51.34 | 2024 | Epkinly |
| Gilead Sciences, INC. | $50.65 | 2019-2023 | |
| Incyte Corporation | $49.36 | 2021 | |
| Astellas Pharma US INC | $36.97 | 2019-2024 | Vyloy |
| Blueprint Medicines Corporation | $36.15 | 2024 | Ayvakit |
| Tesaro, INC. | $28.00 | 2019 | |
| Dendreon Pharmaceuticals LLC | $25.87 | 2024 | Provenge |
| Alexion Pharmaceuticals, INC. | $24.25 | 2024 | Ultomiris |
| Exelixis INC. | $22.09 | 2019 | |
| Myovant Sciences INC. | $21.65 | 2021 | |
| Genentech USA, INC. | $17.19 | 2019 | |
| Syndax Pharmaceuticals, INC. | $16.24 | 2025 | Revuforj |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lipshitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.